Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands.
Int Wound J. 2017 Feb;14(1):142-148. doi: 10.1111/iwj.12574. Epub 2016 Mar 8.
This study sought to evaluate the effectiveness of the inflammatory markers, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), in monitoring treatment of osteomyelitis in the diabetic foot. We screened 150 charts of patients admitted to our hospital with diabetic foot osteomyelitis (DFO), confirmed by positive results of bone culture and/or histopathology. We included patients who had an initial ESR/CRP within 72 hours of admission and two reported follow-up values. We dichotomised patients based on the outcomes wound healing, re-infection, recurrent ulceration, re-hospitalisation, additional surgery, re-amputation and death, all within 12 months, and analysed the trajectories of the markers over time. Our primary outcome, DFO remission, was defined as wound healing within 12 months of follow-up without re-infection. We included 122 subjects; 65 patients (53·3%) had a combination of positive culture and histopathology. Factors associated with DFO remission (n = 46) were a lower white blood count (WBC) at admission (P = 0·006) and a higher glomerular filtration rate (GFR, P = 0·049). Factors associated with healing were a lower WBC (P = 0·004), a higher GFR (P = 0·01), longer wound duration before admission (P = 0·01), location of the ulcer on the great toe (P = 0·01) and higher glycated haemoglobin (P = 0·03). Logistic regression analysis demonstrated no associations between DFO remission and other variables collected. Trajectories of the inflammatory markers showed an association between stagnating values of ESR and CRP and poor clinical outcomes. In this study population, the trajectories of both ESR and CRP during 12 months follow-up suggest a predictive role of both inflammatory markers when monitoring treatment of DFO.
这项研究旨在评估炎症标志物红细胞沉降率(ESR)和 C 反应蛋白(CRP)在监测糖尿病足骨髓炎(DFO)治疗中的有效性。我们筛选了 150 份我院收治的糖尿病足骨髓炎(DFO)患者的病历,这些患者的骨培养和/或组织病理学检查均为阳性。我们纳入了在入院后 72 小时内有初始 ESR/CRP 结果且有两次随访报告的患者。我们根据 12 个月内的伤口愈合、再感染、复发性溃疡、再住院、额外手术、再截肢和死亡等结局将患者分为两组,并分析了标志物随时间的变化轨迹。我们的主要结局是 DFO 缓解,定义为随访 12 个月内伤口愈合且无再感染。我们共纳入 122 例患者,其中 65 例(53.3%)患者的培养和组织病理学均为阳性。与 DFO 缓解相关的因素(n=46)包括入院时白细胞计数(WBC)较低(P=0.006)和肾小球滤过率(GFR)较高(P=0.049)。与愈合相关的因素包括白细胞计数较低(P=0.004)、GFR 较高(P=0.01)、入院前伤口持续时间较长(P=0.01)、溃疡位于大脚趾(P=0.01)和糖化血红蛋白较高(P=0.03)。Logistic 回归分析显示,DFO 缓解与其他收集的变量之间无相关性。炎症标志物的变化轨迹表明,ESR 和 CRP 的停滞值与较差的临床结局之间存在关联。在本研究人群中,ESR 和 CRP 在 12 个月随访期间的变化轨迹表明,这两种炎症标志物在监测 DFO 治疗时具有预测作用。